These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 31985517)

  • 21. Dupilumab-Induced Follicular Conjunctivitis.
    Shen E; Xie K; Jwo K; Smith J; Mosaed S
    Ocul Immunol Inflamm; 2019; 27(8):1339-1341. PubMed ID: 30335586
    [No Abstract]   [Full Text] [Related]  

  • 22. Rosacea associated with dupilumab therapy.
    Heibel HD; Hendricks AJ; Foshee JP; Shi VY
    J Dermatolog Treat; 2021 Feb; 32(1):114-116. PubMed ID: 31132923
    [No Abstract]   [Full Text] [Related]  

  • 23. Management of dupilumab-associated conjunctivitis in atopic dermatitis.
    Aszodi N; Thurau S; Seegräber M; de Bruin-Weller M; Wollenberg A
    J Dtsch Dermatol Ges; 2019 May; 17(5):488-491. PubMed ID: 30873757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report.
    Ludriksone L; Elsner P; Malessa C; Settmacher U; Schliemann S
    J Dtsch Dermatol Ges; 2020 Jul; 18(7):740-742. PubMed ID: 32212242
    [No Abstract]   [Full Text] [Related]  

  • 25. Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis.
    Fukuda K; Ishida W; Kishimoto T; Fukushima A
    Allergol Int; 2019 Jul; 68(3):383-384. PubMed ID: 30718036
    [No Abstract]   [Full Text] [Related]  

  • 26. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
    Ariëns LFM; van der Schaft J; Spekhorst LS; Bakker DS; Romeijn GLE; Kouwenhoven TA; Kamsteeg M; Voorberg AN; Oosting AJ; de Ridder I; Sloeserwij A; Haeck I; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    J Am Acad Dermatol; 2021 Apr; 84(4):1000-1009. PubMed ID: 32946967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement of dupilumab-associated conjunctivitis after switching to upadacitinib in a patient with atopic dermatitis.
    Hayama K; Fujita H
    Dermatol Ther; 2022 Jul; 35(7):e15575. PubMed ID: 35536445
    [No Abstract]   [Full Text] [Related]  

  • 28. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
    Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
    BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting.
    Uchida H; Kamata M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Am Acad Dermatol; 2020 May; 82(5):1247-1249. PubMed ID: 31884090
    [No Abstract]   [Full Text] [Related]  

  • 30. Dupilumab induced ocular surface disease: A prospective case series.
    Pradhan SP; Sadiq SN; Cartes C; Babakinejad P; Ball S; Reynolds NJ; Meggitt S; Figueiredo FC
    Eur J Ophthalmol; 2024 May; 34(3):691-699. PubMed ID: 37644849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
    Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
    J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocular Adverse Events in Patients With Atopic Dermatitis Treated With Upadacitinib: A Real-Life Experience.
    Gelato F; Mastorino L; Quaglino P; Cavaliere G; Ortoncelli M; Ribero S
    Dermatitis; 2023; 34(5):445-447. PubMed ID: 36917522
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-centre experience.
    Simonetti O; Radi G; Diotallevi F; Molinelli E; Rizzetto G; Offidani A
    Clin Exp Dermatol; 2021 Jul; 46(5):939-940. PubMed ID: 33576497
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series.
    Armario-Hita JC; Pereyra-Rodriguez J; Silvestre JF; Ruiz-Villaverde R; Valero A; Izu-Belloso R; Jáuregui-Presa I; Curto-Barredo L; Figueras-Nart I; Herranz-Pinto P; Herraez-Herrera L; Ortiz-de-Frutos FJ; Martinez-Pilar L; Sastre J; Serra-Baldrich E
    Br J Dermatol; 2019 Nov; 181(5):1072-1074. PubMed ID: 31021399
    [No Abstract]   [Full Text] [Related]  

  • 35. Reactivation of Alopecia Areata After Dupilumab Therapy for Atopic Dermatitis.
    Carnicle JM; Hendricks AJ; Shi VY
    Dermatitis; 2021 Oct; 32(1S):e80-e82. PubMed ID: 31441782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dupilumab-associated ocular manifestations: A review of clinical presentations and management.
    Wu D; Daniel BS; Lai AJX; Wong N; Lim DKA; Murrell DF; Lim BXH; Mehta JS; Lim CHL
    Surv Ophthalmol; 2022; 67(5):1419-1442. PubMed ID: 35181280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration.
    Wang Y; Jorizzo JL
    J Am Acad Dermatol; 2021 Apr; 84(4):1010-1014. PubMed ID: 33725800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion.
    Thyssen JP; de Bruin-Weller MS; Paller AS; Leshem YA; Vestergaard C; Deleuran M; Drucker AM; Foelster-Holst R; Traidl-Hoffmann C; Eyerich K; Taieb A; Su JC; Bieber T; Cork MJ; Eichenfield LF; Guttman-Yassky E; Wollenberg A
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1224-1231. PubMed ID: 31056788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe atopic dermatitis: Dupilumab is not just safer, but more efficient.
    Giavina-Bianchi M; Rizzo LV; Giavina-Bianchi P
    Allergol Immunopathol (Madr); 2020; 48(6):792-797. PubMed ID: 32249095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.